Confronto

Carbetocin vs. Pasireotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

37025-55-1

396091-73-9

Peso molecolare

nessun dato

1047.21 g/mol

Emivita

0.67 h

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Carbetocin

Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Carbetocin	Pasireotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Carbetocin and Pasireotid?: Carbetocin is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Carbetocin or Pasireotid?: The highest available evidence level is "RCT sull'uomo" for Carbetocin and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Carbetocin and Pasireotid in Germany and the United States?: Germania: Carbetocin — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Carbetocin — Non approvato, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Carbetocin

Pasireotid

Germania

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Carbetocin and Pasireotid?

Carbetocin is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Carbetocin or Pasireotid?

The highest available evidence level is "RCT sull'uomo" for Carbetocin and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Carbetocin and Pasireotid in Germany and the United States?

Germania: Carbetocin — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Carbetocin — Non approvato, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.